Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Travoprost · 4 trials · 4 indications
IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative change indicates a greater amount of improvement.
| Arm | Type | Description |
|---|---|---|
| Travoprost new formulation | EXPERIMENTAL | Travoprost ophthalmic solution (new formulation), 1 of 3 dose levels, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks |
| TRAVATAN | ACTIVE_COMPARATOR | Travoprost ophthalmic solution 0.004%, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks |
| Vehicle | PLACEBO_COMPARATOR | Inactive ingredients, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks |
| Name | Type | Description |
|---|---|---|
| Travoprost | DRUG | - |
| Latanoprost | DRUG | - |
| Travoprost (0.004%) | DRUG | - |
| Latanoprost (0.005%)/Timolol (0.5%) | DRUG | - |
| Latanoprost (0.005%) | DRUG | - |
| Travoprost ophthalmic solution (new formulation) | DRUG | - |
| Travoprost ophthalmic solution, 0.004% | DRUG | - |
| Vehicle | DRUG | Inactive ingredients used as a placebo |
Adult patients of any race and either sex with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.
Travoprost is used for lowering intraocular pressure in patients with ocular hypertension and glaucoma, including open-angle glaucoma and angle-closure glaucoma. It is a small molecule developed by Alcon Inc. for the ophthalmology therapeutic area and is currently in Phase 3 clinical development.
Travoprost is a prostaglandin analog that works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. It is being studied for its efficacy in treating open-angle glaucoma and ocular hypertension, with clinical trials comparing it to other prostaglandin analogs.
Travoprost is developed by Alcon Inc., a company traded under the ticker symbol ALC. Alcon is conducting clinical trials to evaluate the safety and efficacy of Travoprost in patients with glaucoma and ocular hypertension.
Travoprost is in Phase 3 clinical development. It has completed five clinical trials, including Phase 3 studies, with a total enrollment of 1,549 participants. The drug is investigational and not yet approved by regulatory authorities.
Travoprost has been studied in several clinical trials, including NCT00051142 and NCT00051155, which are Phase 3 trials comparing Travoprost to other glaucoma medications. Additional Phase 2 trials, such as NCT00637130 and NCT01298687, have also been completed to evaluate its safety and efficacy.
Travoprost is also known by the brand name Travatan. Clinical trials, such as NCT01298687, refer to the drug as TRAVATAN, confirming that Travoprost and Travatan are the same medication.